title: Improving population health or the population itself? Health technology assessment and our genetic future.
abstract: The province of British Columbia (BC), Canada is developing its first population-wide prenatal genetic screening program, known as triple-marker screening (TMS). TMS, initiated with a simple blood test, is most commonly used to screen for fetuses with the chromosomal abnormality known as Down syndrome or neural tube disorders. Women testing TMS-positive are offered diagnostic amniocentesis and, if the diagnosis is confirmed, selective second-trimester abortion. The project described in this study was initiated to address the broad range of issues arising from this testing technology and provides an example of the new type of health technology assessment (HTA) contribution emerging (and likely to become increasing necessary) in health policy development. With the advent of prenatal genetic screening programs, would-be parents gain the promise of identifying target conditions and, hence, the option of selective abortion of affected fetuses. There is considerable awareness that these developments pose challenges in every dimension (ethical, political, economic, and clinical) of the health-care environment. In the effort to construct an appropriate prenatal screening policy, therefore, administrators have understandably sought guidance from within the field of HTA. The report authors concluded that, within the restricted path open to it, the role of government is relatively clear. It has the responsibility to maintain equal access to prenatal testing, as to any other health service. It should also require maintenance of medical standards and evaluation of program performance. At the same time, policy-makers need actively to support those individuals born with disabilities and their families.
authors.affiliation: BC Office of Health Technology Assessment, University of British Columbia,Vancouver, Canada. bassett@chspr.ubc.ca
authors.forename: Ken
authors.initials: K
authors.lastname: Bassett
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Lee
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Green
authors.forename: Lisa
authors.initials: L
authors.lastname: Mitchell
authors.forename: Arminée
authors.initials: A
authors.lastname: Kazanjian
mesh_terms: D001955:British Columbia; D003365:Costs and Cost Analysis; D004314:Down Syndrome / Q000175:diagnosis / Q000191:economics; D005053:Eugenics; D005260:Female; D005820:Genetic Testing / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods*; D006291:Health Policy / Q000191:economics / Q000331:legislation & jurisprudence; D006801:Humans; D009035:Mothers / Q000523:psychology; D009436:Neural Tube Defects / Q000175:diagnosis / Q000191:economics; D011050:Policy Making; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics / Q000379:methods*; D013673:Technology Assessment, Biomedical